The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
TDXd demonstrates impressive activity with manageable adverse event profiles in this heavily pretreated population that includes patients with active CNS metastases.
Authors
- Aalya Hamouda (ORCID: https://orcid.org/0000-0003-4531-3943)
- François Patenaude
- Lawrence Panasci (ORCID: https://orcid.org/0000-0002-5141-5594)
- Mark Basik (ORCID: https://orcid.org/0000-0002-2633-5410)
- Parvaneh Fallah
- Anna-Maria Lazaratos (ORCID: https://orcid.org/0000-0003-4923-7159)
- April A. N. Rose (ORCID: https://orcid.org/0000-0002-9845-4603)
- Matthew Dankner (ORCID: https://orcid.org/0000-0003-4869-5895)
- Soumaya Labidi
- Jennifer Friedmann
- Victor Cohen
- Cristiano Ferrario
Institutions
- Jewish General Hospital (CA)
- McGill University (CA)
Publication Details
- Journal
- Current Oncology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.3390/curroncol32010001
- Citations
- 7
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.70